Gilder Gagnon Howe & CO LLC Vaxcyte, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.56 Billion
- Q4 2024
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 16,550 shares of PCVX stock, worth $1.36 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
16,550
Previous 16,508
0.25%
Holding current value
$1.36 Million
Previous $1.88 Million
28.13%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding PCVX
# of Institutions
346Shares Held
130MCall Options Held
534KPut Options Held
248K-
Vanguard Group Inc Valley Forge, PA12MShares$986 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$872 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$820 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$717 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$512 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.89B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...